Coherence’s cancer-sensing brain implant lands in AI’s brain data boom

AI companies have discovered a new frontier for their money, and it sits a few centimeters behind your forehead. Coherence Neuro, a startup building a coin-sized implant that listens to tumors, has become part of a widening wave of AI-adjacent bets on brain data. The company’s disclosed backers, however, do not include OpenAI. The ChatGPT maker’s confirmed neurotech wager is a different company: Merge Labs, the brain-computer interface venture co-founded by Sam Altman. A tumor monitor the size of a coin Coherence was founded in 2022 and works on bioelectronic devices for monitoring and treating cancer. Its flagship system is called SOMA. Tumors produce electrical signals, and SOMA is designed to pick them up. The same device can also deliver stimulation aimed at the tumor. Early preclinical work in mouse models showed the approach could tell healthy brain tissue apart from tissue carrying a tumor. In June 2026, Coherence tested a temporary version of the device in three patients at the Royal Melbourne Hospital. The implant was used during brain surgery, and the goal was to validate safety before longer human trials begin. The company’s longer-term target is glioblastoma, one of the...